Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease—Current Background, Hopes, and Perspectives

Nonalcoholic fatty liver disease (NAFLD) represents the most common chronic liver disease worldwide, reaching one of the highest prevalences in patients with type 2 diabetes mellitus (T2DM). For now, no specific pharmacologic therapies are approved to prevent or treat NAFLD. Glucagon-like peptide-1...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Georgiana-Diana Cazac, Cristina-Mihaela Lăcătușu, Gabriela Ștefănescu, Cătălina Mihai, Elena-Daniela Grigorescu, Alina Onofriescu, Bogdan-Mircea Mihai
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2023-04-01
Edice:	Metabolites
Témata:	fatty liver liver fibrosis steatosis inflammation
On-line přístup:	https://www.mdpi.com/2218-1989/13/5/581
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!